Objective
The overall aim of the ViVac project is to develop and to show safety and efficacy for a new innovative carbohydrate (chitosan) based adjuvant -Viscogel –to be used both in prophylactic and therapeutic vaccination. Three SME participants will contribute with their specific technologies: the unique Viscogel technology, a specific type of cationic peptides with cell-penetrating capacity (LTX) and a technology platform for production of recombinant allergens (Bet v 1). Viscogel has excellent adjuvant properties: strongly immunostimulatory, stable, easy to manufacture, pronounced depot effect and possibility to obtain products of GMP quality. In addition Viscogel is mucoadhesive and in combination with LTX cell penetrating, making it suitable for mucosal administration. The target applications to be demonstrated in the ViVac project are i) prophylactic vaccination against common infectious diseases, and ii) therapeutic allergy vaccination. Both application areas represent billion € markets. Five RTD consortium partners with specific key competences will perform research to support further technical development and new IP opportunities for the participating SME partners. The research objectives are i) to provide pre-clinical and clinical proof-of-concept for prophylactic vaccination with a model vaccine against Hib (Haemophilus influenzae type b). Data supporting that Viscogel induces improved immune responses at lower vaccine doses will likely be applicable to most prophylactic vaccines. ii) to provide pre-clinical proof-of-concept for therapeutic vaccination, demonstrated for allergy vaccination. In particular Viscogel-Bet v 1 formulations for administration over the sublingual mucosa will be developed and thus fulfil an unmet medical need for safe, efficient and convenient allergy vaccination. A successful outcome of the ViVac project will significantly improve the competitive situation for the SME partners and create new commercialisation opportunities.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- natural sciencesbiological sciencesbiochemistrybiomoleculescarbohydrates
- medical and health sciencesclinical medicineallergology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback.
You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Topic(s)
Call for proposal
FP7-SME-2010-1
See other projects for this call
Funding Scheme
BSG-SME - Research for SMEsCoordinator
17163 Solna
Sweden